- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger / Combined Company Re-Named NewcelX Ltd. | 281 | PR Newswire | Combined Company Re-Named NewcelX Ltd., to Commence Trading on the Nasdaq Capital Market on October 31, 2025 under the Ticker Symbol "NCEL"
ZURICH and NESS ZIONA... ► Artikel lesen | |
| Do | NSE/A - NLS Pharmaceutics Ltd. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 1 | SEC Filings | ||
| Do | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| Mi | NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger | 539 | PR Newswire | ZURICH, Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS" or the "Company"), a biopharmaceutical company focused on developing innovative therapies for central nervous system... ► Artikel lesen | |
| Mi | NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem | 145 | PR Newswire | ZURICH, Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company... ► Artikel lesen | |
| NEWCELX Aktie jetzt für 0€ handeln | |||||
| Mi | NLS Pharmaceutics to execute 1-for-10 reverse share split | 1 | Seeking Alpha | ||
| Mi | NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares | 155 | PR Newswire | ZURICH and NESS ZIONA, Israel, Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company") and Kadimastem Ltd. (TASE: KDST) ("Kadimastem") today... ► Artikel lesen | |
| Mo | NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies | 420 | PR Newswire | The collaboration will progress under the combined company, NewCelX, upon completion of the anticipated merger ZURICH and NESS ZIONA, Israel, Oct. 27, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq:... ► Artikel lesen | |
| 23.10. | NLS Pharmaceutics and Kadimastem merger to close Oct. 30 after Nasdaq approval | 2 | Investing.com | ||
| 23.10. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 23.10. | NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025 | 1.841 | PR Newswire | ZURICH, Oct. 23, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (Nasdaq: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system... ► Artikel lesen | |
| 10.10. | Fusion mit Kadimastem: NLS Pharmaceutics reicht Finanzberichte ein | 1 | Investing.com Deutsch | ||
| 10.10. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 30.09. | NLS Pharmaceutics stock tumbles after merger approval with Kadimastem | 3 | Investing.com | ||
| 30.09. | NLS Pharmaceutics: Aktie bricht nach Fusionszustimmung mit Kadimastem ein | 1 | Investing.com Deutsch | ||
| 30.09. | Aktionäre von NLS Pharmaceutics stimmen Fusion mit Kadimastem zu | 2 | Investing.com Deutsch | ||
| 30.09. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 30.09. | NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting | 469 | PR Newswire | Vote clears final corporate milestone, paving the way for the closing of the merger and the combined company of NewCelX Ltd., a Nasdaq-listed biotechnology company ZURICH, Sept. 30, 2025 /PRNewswire/... ► Artikel lesen | |
| 25.09. | NLS Pharmaceutics files to sell 5M common shares for holders | 2 | Seeking Alpha | ||
| 25.09. | NLS Pharmaceutics Ltd. - F-1, Registration statement for certain foreign private issuers | 2 | SEC Filings |
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 69,80 | +0,17 % | Novartis will US-Biotech Avidity Biosciences für 12 Mrd USD übernehmen | DJ Novartis will US-Biotech Avidity Biosciences für 12 Mrd USD übernehmen
Von Dylan Tokar und Peter Loftus
DOW JONES--Novartis will den US-Biotech-Konzern Avidity Biosciences für 12 Milliarden... ► Artikel lesen | |
| QIAGEN | 40,760 | +0,90 % | Dax lässt nach - Merck und Qiagen gefragt | Frankfurt/Main - Zum Wochenausklang hat der Dax nachgelassen. Zum Xetra-Handelsschluss wurde der Index mit 23.958 Punkten berechnet, ein Minus in Höhe von 0,7 Prozent im Vergleich zum Vortagesschluss.... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,500 | -2,31 % | Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock? | ||
| CABALETTA BIO | 3,625 | +47,66 % | Cabaletta Bio Reports Positive Rese-cel Data Across Myositis, SSc, and SLE Trials | ||
| EVOTEC | 7,054 | -0,59 % | EQS-News: Evotec SE: Evotec gibt Fortschritt in präklinischer Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec gibt Fortschritt in präklinischer Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt
27.10.2025 / 07:30 CET/CEST
Für... ► Artikel lesen | |
| BIONTECH | 90,40 | +0,22 % | Turbulenzen im Biotechsektor - BioNTech, CureVac, Moderna, Vidac Pharma | Nach der stetigen Eskalation im Handelskrieg der beiden führenden Wirtschaftsnationen der Welt, USA und China, meldete der US-Finanzminister Scott Bessent, dass er zuversichtlich bezüglich des Treffens... ► Artikel lesen | |
| RANI THERAPEUTICS | 2,185 | +52,80 % | Rani Therapeutics schließt Privatplatzierung ab und besetzt Vorstand neu | ||
| DYNE THERAPEUTICS | 22,580 | -4,08 % | Why Dyne Therapeutics Stock Crushed the Market on Monday | ||
| BEAM THERAPEUTICS | 24,995 | +5,09 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 8,560 | +1,66 % | Morning Market Movers: Ventyx Biosciences, Brera Holdings, Safe & Green Holdings, American Rebel Holdings See Big Swings | CANBERA (dpa-AFX) - At 8:05 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| IMMUNOVANT | 24,700 | -0,44 % | Immunovant gains amid takeover speculation | ||
| INHIBRX BIOSCIENCES | 81,40 | +3,75 % | Morning Market Movers: Picard Medical, Qualigen Therapeutics, Inhibrx Biosciences, MidWestOne Financial GroupSee Big Swings | BEIJING (dpa-AFX) - At 7:45 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 25,320 | +1,61 % | Arcutis Biotherapeutics, Inc.: Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results | Q3 2025 net product revenue for ZORYVE® (roflumilast) was $99.2 million, a 122% increase compared to Q3 of 2024, and a 22% increase compared to Q2 of 2025 ZORYVE cream 0.05% received U.S. Food and... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 18,900 | +1,45 % | Summit Therapeutics: A Risky Bet in the Biotech Arena? | ||
| MODERNA | 23,620 | -1,11 % | Watch Cigna, Moderna, Reddit, and More |
NEWCELX LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 7,200 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEWCELX LTD finden Sie auf Wallstreet Online.